You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Remoxipride hydrochloride
Remoxipride hydrochloride is a dopamine D2 receptor antagonist showing selectivity over D3 and D4 receptors (Ki values are ~ 300, ~ 1600, and ~ 2800 nM for D2, D3 and D4 receptors respectively). Exhibits antipsychotic activity in vivo with no extrapyramidal side effects. 50-fold more potent than sulpiride in antagonising the effects of apomorphine in the rat.
Technical Data for Remoxipride hydrochloride
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Remoxipride hydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Remoxipride hydrochloride
The following data is based on the product molecular weight 407.73. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.45 mL||12.26 mL||24.53 mL|
|5 mM||0.49 mL||2.45 mL||4.91 mL|
|10 mM||0.25 mL||1.23 mL||2.45 mL|
|50 mM||0.05 mL||0.25 mL||0.49 mL|
Product Datasheets for Remoxipride hydrochloride
References for Remoxipride hydrochloride
References are publications that support the biological activity of the product.
Ahlenius et al (1997) In vivo effects of remoxipride and aromatic ring metabolites in the rat. J.Pharmacol.Exp.Ther. 283 1356 PMID: 9400011
Mohell et al (1993) Binding characteristics of remoxipride and its metabolites to DA D2 and D3 receptors. Eur.J.Pharmacol. 238 121 PMID: 8405075
Sedvall (1990) Development of a new antipsychotic remoxipride. Acta Psychiatr.Scand.Suppl. 358 1 PMID: 1978466
Seeman and Van Tol (1994) DA receptor pharmacology. TiPS 15 264 PMID: 7940991
If you know of a relevant reference for Remoxipride hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Remoxipride hydrochloride, Remoxipride hydrochloride supplier, selective, D2-like, antagonists, dopamine, non-selective, receptor, antagonist, dopaminergic, d2, Non-selective, Dopamine, 0916, Tocris Bioscience
1 Citation for Remoxipride hydrochloride
Citations are publications that use Tocris products. Selected citations for Remoxipride hydrochloride include:
André et al (2011) Differential electrophysiological changes in striatal output neurons in Huntington's disease. J Neurosci 31 1170 PMID: 21273402
Do you know of a great paper that uses Remoxipride hydrochloride from Tocris? Please let us know.
Reviews for Remoxipride hydrochloride
There are currently no reviews for this product. Be the first to review Remoxipride hydrochloride and earn rewards!
Have you used Remoxipride hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.